$2.60
+0.04 (+1.56%)
Open$2.54
Previous Close$2.56
Day High$2.69
Day Low$2.43
52W High$19.35
52W Low$1.70
Volume—
Avg Volume54.4K
Market Cap24.95M
P/E Ratio—
EPS$-4.34
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+223.8% upside
Current
$2.60
$2.60
Target
$8.42
$8.42
$5.85
$8.42 avg
$9.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.66M | 19.11M | 19.03M |
| Net Income | -1,423,753 | -1,667,488 | -1,447,772 |
| Profit Margin | -6.6% | -8.7% | -7.6% |
| EBITDA | -1,912,051 | -1,729,452 | -1,852,839 |
| Free Cash Flow | -992,506 | -967,985 | -917,697 |
| Rev Growth | +8.7% | -4.8% | +0.2% |
| Debt/Equity | 0.16 | 0.13 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |